Common TitlePEARL-II
Official Title ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response with or without Ribavirin in Treatment-Experienced Patients with HCV Genotype 1b Infection
Phase Phase III
ClinicalTrials.gov NCT01674725
Treatments
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:DiscontinuedFunding
IndustryAbbVie